Multi-country oncology trial share vs Cell and gene therapy venture capital and public funding deal count

Multi-country oncology trial share and Cell and gene therapy venture capital and public funding deal count worldwide, compared over time.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Multi-country oncology trial share

Unit: % · 2 observations

Line chart
Multi-country oncology trial shareMulti-country oncology trial share. 2 observations from 2015 to 2024, ranging from 20% to 37%. Latest value 20% (2024). % 0 10 20 30 40 2015 2017 2019 2021 2023 37% 20%
Multi-country oncology trial shareMulti-country oncology trial share. 2 observations from 2015 to 2024, ranging from 20% to 37%. Latest value 20% (2024). % 0 10 20 30 40 2015 2017 2019 2021 2023 37% 20%
Multi-country oncology trial shareMulti-country oncology trial share. 2 observations from 2015 to 2024, ranging from 20% to 37%. Latest value 20% (2024). % 0 10 20 30 40 2015 2017 2019 2021 2023 37% 20%
View the underlying data
Multi-country oncology trial share
Period Type Value
2015 Actual 37%
2024 Actual 20%
Source: IQVIA · CC BY 4.0 · Full series

Cell and gene therapy venture capital and public funding deal count

Unit: count · 3 observations

Line chart
Cell and gene therapy venture capital and public funding deal countCell and gene therapy venture capital and public funding deal count. 3 observations from 2021 to 2023, ranging from 96 to 127. Latest value 96 (2023). 0 30 60 90 120 150 2015 2017 2019 2021 2023 127 96
Cell and gene therapy venture capital and public funding deal countCell and gene therapy venture capital and public funding deal count. 3 observations from 2021 to 2023, ranging from 96 to 127. Latest value 96 (2023). 0 50 100 150 2015 2017 2019 2021 2023 127 96
Cell and gene therapy venture capital and public funding deal countCell and gene therapy venture capital and public funding deal count. 3 observations from 2021 to 2023, ranging from 96 to 127. Latest value 96 (2023). 0 50 100 150 2015 2017 2019 2021 2023 127 96
View the underlying data
Cell and gene therapy venture capital and public funding deal count
Period Type Value
2021 Actual 127
2022 Actual 97
2023 Actual 96
Source: IQVIA · CC BY 4.0 · Full series

Provenance

Where these numbers come from

Multi-country oncology trial share

Share of oncology trial starts that were multi-country studies.

2 observations in Global · source organisations: IQVIA

Cell and gene therapy venture capital and public funding deal count

Number of venture capital and public funding transactions for cell and gene therapies in a given year.

3 observations in Global · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related